258 related articles for article (PubMed ID: 31386368)
1. HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2' Ligands To Optimize Hydrogen Bonding in the Substrate Envelope.
Rusere LN; Lockbaum GJ; Lee SK; Henes M; Kosovrasti K; Spielvogel E; Nalivaika EA; Swanstrom R; Yilmaz NK; Schiffer CA; Ali A
J Med Chem; 2019 Sep; 62(17):8062-8079. PubMed ID: 31386368
[TBL] [Abstract][Full Text] [Related]
2. Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies.
Ghosh AK; Kovela S; Osswald HL; Amano M; Aoki M; Agniswamy J; Wang YF; Weber IT; Mitsuya H
J Med Chem; 2020 May; 63(9):4867-4879. PubMed ID: 32348139
[TBL] [Abstract][Full Text] [Related]
3. Design and evaluation of novel piperidine HIV-1 protease inhibitors with potency against DRV-resistant variants.
Zhu M; Zhou H; Ma L; Dong B; Zhou J; Zhang G; Wang M; Wang J; Cen S; Wang Y
Eur J Med Chem; 2021 Aug; 220():113450. PubMed ID: 33906049
[TBL] [Abstract][Full Text] [Related]
4. P2' benzene carboxylic acid moiety is associated with decrease in cellular uptake: evaluation of novel nonpeptidic HIV-1 protease inhibitors containing P2 bis-tetrahydrofuran moiety.
Yedidi RS; Maeda K; Fyvie WS; Steffey M; Davis DA; Palmer I; Aoki M; Kaufman JD; Stahl SJ; Garimella H; Das D; Wingfield PT; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2013 Oct; 57(10):4920-7. PubMed ID: 23877703
[TBL] [Abstract][Full Text] [Related]
5. Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis.
Ghosh AK; R Nyalapatla P; Kovela S; Rao KV; Brindisi M; Osswald HL; Amano M; Aoki M; Agniswamy J; Wang YF; Weber IT; Mitsuya H
J Med Chem; 2018 May; 61(10):4561-4577. PubMed ID: 29763303
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres.
Reddy GS; Ali A; Nalam MN; Anjum SG; Cao H; Nathans RS; Schiffer CA; Rana TM
J Med Chem; 2007 Sep; 50(18):4316-28. PubMed ID: 17696512
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel HIV-1 protease inhibitors with pentacyclic triterpenoids as P2-ligands.
Zhu M; Du XN; Li YG; Zhang GN; Wang JX; Wang YC
Bioorg Med Chem Lett; 2019 Feb; 29(3):357-361. PubMed ID: 30580917
[TBL] [Abstract][Full Text] [Related]
8. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
Ali A; Reddy GS; Cao H; Anjum SG; Nalam MN; Schiffer CA; Rana TM
J Med Chem; 2006 Dec; 49(25):7342-56. PubMed ID: 17149864
[TBL] [Abstract][Full Text] [Related]
9. Design and biological evaluation of novel HIV-1 protease inhibitors with isopropanol as P1' ligand to enhance binding with S1' subsite.
Zhu M; Ma L; Dong B; Zhang G; Wang J; Zhou J; Cen S; Wang Y
Bioorg Med Chem; 2020 Aug; 28(16):115623. PubMed ID: 32690263
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones.
Ali A; Reddy GS; Nalam MN; Anjum SG; Cao H; Schiffer CA; Rana TM
J Med Chem; 2010 Nov; 53(21):7699-708. PubMed ID: 20958050
[TBL] [Abstract][Full Text] [Related]
11. Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.
Ghosh AK; Gemma S; Baldridge A; Wang YF; Kovalevsky AY; Koh Y; Weber IT; Mitsuya H
J Med Chem; 2008 Oct; 51(19):6021-33. PubMed ID: 18783203
[TBL] [Abstract][Full Text] [Related]
12. Novel Protease Inhibitors Containing C-5-Modified
Takamatsu Y; Aoki M; Bulut H; Das D; Amano M; Sheri VR; Kovari LC; Hayashi H; Delino NS; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31085520
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands.
Qiu X; Zhao GD; Tang LQ; Liu ZP
Bioorg Med Chem Lett; 2014 Jun; 24(11):2465-8. PubMed ID: 24767846
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.
Ghosh AK; Sean Fyvie W; Brindisi M; Steffey M; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
Bioorg Med Chem Lett; 2017 Nov; 27(21):4925-4931. PubMed ID: 28958624
[TBL] [Abstract][Full Text] [Related]
15. Potent HIV-1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein-Ligand X-ray Structural Studies.
Ghosh AK; Xia Z; Kovela S; Robinson WL; Johnson ME; Kneller DW; Wang YF; Aoki M; Takamatsu Y; Weber IT; Mitsuya H
ChemMedChem; 2019 Nov; 14(21):1863-1872. PubMed ID: 31549492
[TBL] [Abstract][Full Text] [Related]
16. GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants.
Delino NS; Aoki M; Hayashi H; Hattori SI; Chang SB; Takamatsu Y; Martyr CD; Das D; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463535
[TBL] [Abstract][Full Text] [Related]
17. Preliminary SAR and biological evaluation of potent HIV-1 protease inhibitors with pyrimidine bases as novel P2 ligands to enhance activity against DRV-resistant HIV-1 variants.
Zhu M; Ma L; Zhou H; Dong B; Wang Y; Wang Z; Zhou J; Zhang G; Wang J; Liang C; Cen S; Wang Y
Eur J Med Chem; 2020 Jan; 185():111866. PubMed ID: 31734023
[TBL] [Abstract][Full Text] [Related]
18. Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy.
Lindberg J; Pyring D; Löwgren S; Rosenquist A; Zuccarello G; Kvarnström I; Zhang H; Vrang L; Classon B; Hallberg A; Samuelsson B; Unge T
Eur J Biochem; 2004 Nov; 271(22):4594-602. PubMed ID: 15560801
[TBL] [Abstract][Full Text] [Related]
19. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
Jadhav PK; Ala P; Woerner FJ; Chang CH; Garber SS; Anton ED; Bacheler LT
J Med Chem; 1997 Jan; 40(2):181-91. PubMed ID: 9003516
[TBL] [Abstract][Full Text] [Related]
20. Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate -- interactions with frequently occurring glutamic acid residue at P2' position of substrates.
Weber IT; Wu J; Adomat J; Harrison RW; Kimmel AR; Wondrak EM; Louis JM
Eur J Biochem; 1997 Oct; 249(2):523-30. PubMed ID: 9370363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
